[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630103":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":49,"centralContacts":54,"locations":60,"responsibleParty":74,"collaborators":77,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":36,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":36,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":107,"overallStatus":114,"whyStopped":36,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Spaulding Rehabilitation Hospital","OTHER",[8,15,21,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1 - Control Exercise Therapy + Sham PRP + Sham Shockwave","SHAM_COMPARATOR","A sham PRP injection will be performed where the needle breaks the skin but does not fenestrate the tendon. The sham ESWT will include radial pressure waves and focused shockwaves delivered without the device turned on to deliver energy and audio recording. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.",[13,14],"Device: Sham PRP","Device: Sham ESWT",{"label":16,"type":17,"description":18,"interventionNames":19},"Arm 2 - Exercise Therapy + Platelet-Rich Plasma (PRP) + Sham Shockwave","EXPERIMENTAL","PRP will be delivered around the tendon, sham ESWT will be issued. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.",[20,14],"Device: Platelet Rich Plasma",{"label":22,"type":17,"description":23,"interventionNames":24},"Arm 3 - Exercise Therapy + Extracorporeal Shockwave Therapy (ESWT) + Sham PRP","Sham PRP will be delivered. Three sessions of ESWT will be delivered to the Achilles tendon. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.",[25,13],"Device: Extracorporeal Shockwave Therapy",{"label":27,"type":17,"description":28,"interventionNames":29},"Arm 4 - Exercise Therapy + Platelet-Rich Plasma + Extracorporeal Shockwave Therapy","PRP will be administered followed by three sessions of ESWT. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.",[20,25],[31,37,41,45],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DEVICE","Platelet Rich Plasma","Participants randomized to PRP will receive a single ultrasound-guided injection of approximately 3 mL of neutrophil-poor platelet-rich plasma derived from autologous blood. Blood will be processed to concentrate platelets and the PRP will be injected adjacent to the Achilles tendon at the site of maximal pain.",[16,27],null,{"type":32,"name":38,"description":39,"armGroupLabels":40,"otherNames":36},"Extracorporeal Shockwave Therapy","Participants randomized to ESWT will receive three weekly treatment sessions. Focused shockwave therapy will deliver approximately 2000 shocks with gradual energy escalation, followed by radial shockwave therapy delivering approximately 3000 pulses to the Achilles tendon and 3000 pulses to surrounding musculature.",[22,27],{"type":32,"name":42,"description":43,"armGroupLabels":44,"otherNames":36},"Sham PRP","A needle will be inserted but no injection will occur around the Achilles tendon",[9,22],{"type":32,"name":46,"description":47,"armGroupLabels":48,"otherNames":36},"Sham ESWT","Both focused shockwave and radial pressure wave will be in contact with the skin, but the devices will not be active to deliver energy. An audio recording will provide noises similar to the machines operating.",[9,16],[50],{"name":51,"affiliation":52,"role":53},"Adam S. Tenforde, MD","Spaulding Rehabiltaition Hospital","PRINCIPAL_INVESTIGATOR",[55],{"name":56,"role":57,"phone":58,"phoneExt":36,"email":59},"Sydney Karnovsky, MD","CONTACT","(862) 216-8050","skarnovsky@mgb.org",[61],{"facility":62,"status":36,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":36},"Spaulding Cambridge Hospital","Cambridge","Massachusetts","02138","United States","US",{"type":69,"coordinates":70},"Point",[71,72],-71.10561,42.3751,{"lat":72,"lon":71},{"type":53,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"Adam Tenforde","Associate Professor, Harvard Medical School",[78,81],{"name":79,"class":80},"Storz Medical AG","INDUSTRY",{"name":82,"class":6},"Foundation for Physical Medicine and Rehabilitation","100630103","extracorporeal-shockwave-therapy-and-platelet-rich-plasma-for-midportion-achilles-tendinopathy-100630103",false,"NCT07483320","Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy","A Randomized Controlled Trial Evaluating the Influence of Physical Therapy, Shockwave Therapy, Platelet Rich Plasma or Combined Treatment in the Management of Midportion Achilles Tendinopathy","Inclusion Criteria:\n\n* Age 18-65 years\n* Diagnosis of unilateral midportion Achilles tendinopathy\n* Symptoms present for more than 3 months\n* VISA-A score \\\u003C80 at baseline\n* Pre-injury physical activity level ≥3 on the Physical Activity Scale\n* Ability to participate in rehabilitation program\n\nExclusion Criteria:\n\n* Symptoms present for less than 3 months\n* Prior PRP injection or ESWT treatment to the Achilles tendon within 3 months\n* Other lower extremity musculoskeletal injury affecting function\n* Symptomatic arthritis affecting the ankle or foot\n* Rheumatologic disease or connective tissue disorder\n* Coagulopathy or anticoagulant therapy affecting platelet function\n* Neuropathy affecting pain perception\n* Known cardiac condition contraindicating treatment\n* Poorly controlled diabetes (HbA1c \\>9.0)\n* Pregnancy","ALL","18 Years","65 Years",{"count":94,"type":95},100,"ESTIMATED","INTERVENTIONAL",[98],"NA","Midportion Achilles tendinopathy is a common cause of pain and functional limitation in both athletes and the general population. Progressive tendon loading programs are considered first-line treatment but do not lead to satisfactory outcomes in all patients. Extracorporeal shockwave therapy (ESWT) and platelet-rich plasma (PRP) injections are commonly used interventions for refractory symptoms, yet evidence supporting their combined use is limited particularly in treating Achilles tendon disorders.\n\nThis randomized controlled trial will evaluate the effectiveness of a standardized exercise program alone or in combination with PRP injection, ESWT, or both therapies in active adults with midportion Achilles tendinopathy. Participants will be randomized to one of four treatment groups and followed for six months. The primary outcome will assess changes in Achilles tendon symptoms and function using the Victorian Institute of Sport Assessment-Achilles (VISA-A) score. Secondary outcomes will include patient-reported outcomes, physical function testing, ultrasound tendon structure measures, and gait biomechanics.",[101,102,103,104,105,106],"Achilles Injuries Tendon","Achilles Tendinopathy (AT)","Achilles Tendinitis, Left Leg","Achilles Tendinitis, Right Leg","Achilles Tendon Pain","Achilles Tendonitis",[108,109,110,111,112,113],"PRP","platelet rich plasma","extracorporeal shockwave","focus shockwave","radial pressure waves","rehabilitation","NOT_YET_RECRUITING","2026-05-08",{"date":117,"type":118},"2026-05-13","ACTUAL",{"date":120,"type":95},"2026-06-01",{"date":122,"type":95},"2028-05-30",{"name":5,"class":6},1]